Stayble Therapeutics Past Earnings Performance
Past criteria checks 0/6
Stayble Therapeutics's earnings have been declining at an average annual rate of -20.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 84.2% per year.
Key information
-20.4%
Earnings growth rate
17.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | -84.2% |
| Return on equity | -166.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Stayble Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -20 | 21 | 0 |
| 31 Mar 24 | 0 | -24 | 24 | 0 |
| 31 Dec 23 | 0 | -24 | 24 | 0 |
| 30 Sep 23 | 0 | -22 | 22 | 0 |
| 30 Jun 23 | 0 | -21 | 21 | 0 |
| 31 Mar 23 | 0 | -21 | 21 | 0 |
| 31 Dec 22 | 0 | -25 | 25 | 0 |
| 30 Sep 22 | 0 | -25 | 25 | 0 |
| 30 Jun 22 | 0 | -22 | 22 | 0 |
| 31 Mar 22 | 0 | -18 | 18 | 0 |
| 31 Dec 21 | 0 | -12 | 12 | 0 |
| 30 Sep 21 | 0 | -9 | 8 | 0 |
| 30 Jun 21 | 0 | -8 | 8 | 0 |
| 31 Mar 21 | 0 | -12 | 12 | 0 |
| 31 Dec 20 | 0 | -15 | 15 | 0 |
| 30 Sep 20 | 1 | -18 | 17 | 0 |
| 30 Jun 20 | 1 | -16 | 16 | 0 |
| 31 Mar 20 | 1 | -11 | 11 | 0 |
| 31 Dec 19 | 1 | -7 | 7 | 0 |
| 30 Sep 19 | 0 | -5 | 5 | 0 |
| 31 Dec 18 | 0 | -6 | 6 | 0 |
| 31 Dec 17 | 0 | -3 | 3 | 0 |
| 31 Dec 16 | 0 | -1 | 0 | 0 |
Quality Earnings: STABL is currently unprofitable.
Growing Profit Margin: STABL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STABL is unprofitable, and losses have increased over the past 5 years at a rate of 20.4% per year.
Accelerating Growth: Unable to compare STABL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STABL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).
Return on Equity
High ROE: STABL has a negative Return on Equity (-166.93%), as it is currently unprofitable.